Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry

Oct 2019| PHM220A| BCC Publishing

Report Highlights

This report provides information on significant drug launches in 2019. The study provides an overview of each drug, scientific summaries, pharmacodynamics, pharmacokinetics and clinical trial information, disease backgrounds, analysis of the market, competitors and company profiles of manufacturers. The objective of this study is to present a comprehensive analysis of the current market and its future direction.

Report Includes

  • Information on the top potential drug launches by pharma companies in 2019
  • Knowledge about drug, mechanism of action, and briefing of clinical evidences
  • Detailed information and insights on the drug Upadacitinib which is manufactured by AbbVie Inc. , Ultomiris (ravulizumab-cwvz) a humanized monoclonal antibody manufactured by Alexion Pharmaceuticals Inc. and many more
  • Insights into regulatory approvals, market scope, and analysis of pipeline molecules
  • Detailed profiles of the companies and competitors related to the industry

Report Scope

The current report provides details about drug molecules that have been or will be launched in the market in 2019. This report highlights information and insights on the molecules. The report includes drug overviews, mechanisms of action, disease backgrounds, currently available treatments for diseases that these drugs address, clinical evidence on safety and efficacy, regulatory scenarios, market scope of the drugs and company profiles of manufactures.

Analyst Credentials

BCC Publishing Staff comprises expert analysts who are skilled in conducting primary research, secondary research and data analysis and have decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies. Collectively, the team represents a diverse set of educational achievements with individual graduate work completed in fields such as microbiology, electrical engineering, business administration and surgery, among others.

Latest reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at
Title/Chapter NamePagesPrice Member Price
Full Report: Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry127 $2,750 Free
Chapter- 1: Introduction3Free
Chapter- 2: Significant Drug Launches5$250Free
Chapter- 3: Ultomiris (Ravulizumab)11$246Free
Chapter- 4: Rinvoq (Upadacitinib)17$380Free
Chapter- 5: Drug XX15$335Free
Chapter- 6: Drug XX10$224Free
Chapter- 7: Drug XX10$224Free
Chapter- 8: Drug XX8$179Free
Chapter- 9: Drug XX11$246Free
Chapter- 10: Drug XX11$246Free
Chapter- 11: Drug XX7$157Free
Chapter- 12: Drug XX13$291Free
Chapter- 13: Conclusion2$45Free
Chapter- 14: Appendix: Acronyms4$89Free
Significant Drug Launches in 2019: A BCC Research Analysis and Insights on Pharmaceutical Industry

Single User License: $2750

Become a Member

Already a member? Login to access this report free.

Have a Question? Ask Us.

Why BCC Research.?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries